Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q1 CY2026 Sales Beat Estimates

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 38.6% year on year to $207.7 million. On the other hand, the company’s full-year revenue guidance of $855 million at the midpoint came in 0.8% below analysts’ estimates. Its GAAP loss of $0.04 per share was $0.03 below analysts’ consensus estimates.

Is now the time to buy Supernus Pharmaceuticals? Find out by accessing our full research report, it’s free.

“Our first quarter results reflect a strong start to the year, including a 56% year-over-year increase in combined revenues of our growth products,” said Jack Khattar, President and CEO of Supernus.

Company Overview

With a diverse portfolio of eight FDA-approved medications targeting neurological conditions, Supernus Pharmaceuticals (NASDAQ:SUPN) develops and markets treatments for central nervous system disorders including epilepsy, ADHD, Parkinson's disease, and migraine.

Revenue Growth

A company’s long-term performance is an indicator of its overall quality. Any business can have short-term success, but a top-tier one grows for years. Over the last five years, Supernus Pharmaceuticals grew its sales at a mediocre 5.8% compounded annual growth rate. This was below our standard for the healthcare sector and is a rough starting point for our analysis.

We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Supernus Pharmaceuticals’s annualized revenue growth of 17.3% over the last two years is above its five-year trend, suggesting its demand recently accelerated.

This quarter, Supernus Pharmaceuticals reported wonderful year-on-year revenue growth of 38.6%, and its $207.7 million of revenue exceeded Wall Street’s estimates by 7.7%.

Looking ahead, sell-side analysts expect revenue to grow 16.8% over the next 12 months, similar to its two-year rate. This projection is noteworthy and implies the market sees success for its products and services.

WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.

This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.

Adjusted Operating Margin

Adjusted operating margin is a key measure of profitability. Think of it as net income (the bottom line) excluding the impact of non-recurring expenses, taxes, and interest on debt - metrics less connected to business fundamentals.

Supernus Pharmaceuticals has been an efficient company over the last five years. It was one of the more profitable businesses in the healthcare sector, boasting an average adjusted operating margin of 22.4%.

Analyzing the trend in its profitability, Supernus Pharmaceuticals’s adjusted operating margin decreased by 8.7 percentage points over the last five years. The company’s two-year trajectory also shows it failed to get its profitability back to the peak as its margin fell by 4.9 percentage points. This performance was poor no matter how you look at it - it shows its expenses were rising and it couldn’t pass those costs onto its customers.

This quarter, Supernus Pharmaceuticals generated an adjusted operating margin profit margin of negative 4%, down 21.3 percentage points year on year. This contraction shows it was less efficient because its expenses grew faster than its revenue.

Earnings Per Share

Revenue trends explain a company’s historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions.

Sadly for Supernus Pharmaceuticals, its EPS declined by 17.6% annually over the last five years while its revenue grew by 5.8%. This tells us the company became less profitable on a per-share basis as it expanded.

Diving into the nuances of Supernus Pharmaceuticals’s earnings can give us a better understanding of its performance. As we mentioned earlier, Supernus Pharmaceuticals’s adjusted operating margin declined by 8.7 percentage points over the last five years. Its share count also grew by 6.4%, meaning the company not only became less efficient with its operating expenses but also diluted its shareholders.

In Q1, Supernus Pharmaceuticals reported EPS of negative $0.04, up from negative $0.21 in the same quarter last year. Despite growing year on year, this print missed analysts’ estimates. We also like to analyze expected EPS growth based on Wall Street analysts’ consensus projections, but there is insufficient data.

Key Takeaways from Supernus Pharmaceuticals’s Q1 Results

We were impressed by how significantly Supernus Pharmaceuticals blew past analysts’ revenue expectations this quarter. We were also glad its full-year operating income guidance slightly exceeded Wall Street’s estimates. On the other hand, its EPS was in line and its full-year revenue guidance fell slightly short of Wall Street’s estimates. Overall, this was a softer quarter. The stock remained flat at $49.10 immediately following the results.

Is Supernus Pharmaceuticals an attractive investment opportunity at the current price? What happened in the latest quarter matters, but not as much as longer-term business quality and valuation, when deciding whether to invest in this stock. We cover that in our actionable full research report which you can read here (it’s free).